This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Mauro MJ, O‘Dwyer M, Heinrich MC, Druker BJ . STI571: a paradigm of new agents for cancer therapeutics J Clin Oncol 2002 20: 325–334
Pinilla-Ibarz J, Cathcart K, Scheinberg DA . CML vaccines as a paradigm of the specific immunotherapy of cancer Blood Rev 2000 14: 111–120
Melo JV, Gordon DE, Cross NC, Goldman JM . The ABL-BCR fusion gene is expressed in chronic myeloid leukemia Blood 1993 81: 158–165
Berke Z, Andersen MH, Pedersen M, Fugger L, Zeuthen J, Haurum JS . Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules Leukemia 2000 14: 419–426
Huntly BJP, Reid AG, Bench AJ, Campbell LJ, Telford N, Shepherd P, Szer J, Prince HM, Turner P, Grace C, Nacheva EP, Green AR . Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia Blood 2001 98: 1732–1738
Clark RE, Dodi IA, Hill SC, Lill JR, Aubert G, Macintyre AR, Rojas J, Bourdon A, Bonner PLR, Wang L, Christmas SE, Travers PJ, Creaser CS, Rees RC, Madrigal JA . Direct evidence that leukaemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein Blood 2001 98: 2887–2893
Knights AJ, Zaniou A, Rees RC, Pawelec G, Müller L . Prediction of an HLA-DR-binding peptide derived from Wilms’ tumour 1 protein and demonstration of in vitro immunogenicity of WT1(124-138)-pulsed dendritic cells generated according to an optimised protocol Cancer Immunol Immunother 2002 51: 271–281
Pawelec G, Max H, Halder T, Bruserud O, Merl A, da Silva P, Kalbacher H . BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors Blood 1996 88: 2118–2124
Acknowledgements
We would like to thank Dr Medi Adibzadeh, Tübingen, for helping to initiate these studies, Prof W Voelter and Dr Hubert Kalbacher for peptide synthesis and Dr Martin Deeg for assistance with mass spectrometry. We thank Prof Jesper Zeuthen for providing class-I peptides and Prof CA Müller for HLA typing. We thank the patients who provided blood samples and their physicians for making them available for this study. This work was supported by the Mildred Scheel Foundation for Cancer Research (Deutsche Krebshilfe) Grant No. 10-1173-Pa3 and the Dieter Schlag Foundation for Research into Diseases of the Blood. The peptide sensitization protocols were developed as part of an EU collaborative project (EUCAPS, contract BMH4-CT98-3058, coordinated by G Pawelec).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wagner, W., Ouyang, Q. & Pawelec, G. Peptides spanning the fusion region of Abl/Bcr are immunogenic and sensitize CD8+ T lymphocytes to recognize native chronic myelogenous leukemia. Leukemia 16, 2341–2343 (2002). https://doi.org/10.1038/sj.leu.2402687
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402687